DEFA14A: NovaBay Pharmaceuticals to Sell Eyecare Business, Plans Liquidation After Revised Deal

NovaBay Pharmaceuticals has agreed to sell its Avenova eyecare business to PRN Physician Recommended Nutriceuticals for $11.5 million, up from a previous $9.5 million, and plans to liquidate the company.

Summary

• NovaBay Pharmaceuticals is selling its Avenova eyecare business to PRN Physician Recommended Nutriceuticals for $11.5 million, an increase from the originally agreed $9.5 million.
• The deal includes a bridge loan of up to $1 million from PRN to NovaBay, split into two $500,000 installments.
• The company plans to liquidate and dissolve after the sale, distributing remaining assets to stockholders.
• NovaBay has faced financial challenges and has publicly stated doubts about its ability to continue as a going concern.
• The company's board believes the asset sale and dissolution are in the best interests of stockholders.
• The increased purchase price is expected to result in additional cash proceeds for distribution to stockholders after repaying the bridge loan.
• Stockholders will vote on the asset sale and dissolution at a special meeting on November 22, 2024.
• The company estimates stockholders will receive between $0.13 and $1.02 per share after the sale and liquidation, though this is subject to various factors.
• The sale is expected to close in the fourth quarter of 2024, pending stockholder approval and other closing conditions.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the increased sale price and bridge loan are positive, the overall context of liquidation and financial difficulties creates a neutral to slightly negative outlook. The uncertainty around the final distribution to stockholders also contributes to the moderate sentiment score.

Positives

• The increased sale price of $11.5 million provides more funds for distribution to stockholders.
• The bridge loan of up to $1 million provides additional liquidity to NovaBay.
• The board of directors unanimously supports the asset sale and dissolution.
• The deal removes debt financing contingencies for PRN, adding a representation that PRN has sufficient funding.
• An equity funding commitment letter from RoundTable Healthcare Partners provides up to $13 million in financing to PRN's parent company.

Negatives

• NovaBay has faced significant financial and operational challenges.
• The company has publicly disclosed substantial doubt about its ability to continue as a going concern.
• The company's operations are not sustainable beyond the first quarter of 2025 without the sale.
• If the asset sale is not completed, NovaBay will need to repay the bridge loan and may need to pursue other capital raising options or file for bankruptcy.
• The estimated distribution to stockholders is subject to various factors and could be less than the estimated range or even result in no payout.

Risks

• The asset sale and dissolution may not be completed.
• If the asset sale is not completed, NovaBay will have limited capital to operate and repay the bridge loan.
• The company may need to pursue capital raising options or other strategic alternatives if the sale fails.
• The terms of an alternative transaction may be less favorable than the current asset sale.
• The company may not have enough funds to continue operating its business if the sale or another transaction is not completed.
• The amount of distributions to stockholders is uncertain and could be less than estimated or even zero.
• The bridge loan is secured by all of NovaBay's assets, which could be at risk if the sale does not close.

Future Outlook

The company expects to complete the asset sale in the fourth quarter of 2024, subject to stockholder approval and other closing conditions. After the sale, the company plans to liquidate and dissolve, distributing remaining assets to stockholders. The exact timing of the liquidation and distribution is not yet known.

Management Comments

• The Board of Directors determined that the Asset Sale pursuant to the Asset Purchase Agreement and the Dissolution pursuant to the Plan of Dissolution are advisable and in the best interests of stockholders.
• The Board of Directors unanimously recommends that you vote FOR the proposed Asset Sale as provided in Proposal One in the Proxy Statement and the proposed Dissolution pursuant to the Plan of Dissolution set forth in Proposal Two of the Proxy Statement.

Industry Context

This announcement reflects a trend of smaller pharmaceutical companies facing financial difficulties and seeking strategic alternatives, including asset sales and liquidation. The sale of the eyecare business suggests a focus on core competencies or a strategic shift away from this sector. The increased purchase price indicates a competitive market for assets in this space.

Comparison to Industry Standards

• The initial offer of $9.5 million was increased to $11.5 million after a competing offer was received, suggesting that the initial valuation may have been below market value.
• The use of a bridge loan is a common practice in acquisitions to provide short-term funding.
• The estimated distribution of $0.13 to $1.02 per share is highly variable and depends on several factors, including the sale of other assets and the amount of liabilities.
• The liquidation process is a common outcome for companies facing financial distress, but the return to shareholders is often uncertain and can be minimal.
• The timeline for the sale and liquidation is relatively short, indicating a desire to quickly resolve the company's financial issues.

Stakeholder Impact

• Shareholders will receive a distribution of remaining assets after the sale and liquidation, though the amount is uncertain.
• Employees of the Avenova business may be offered employment by PRN.
• Customers of the Avenova business will be transitioned to PRN.
• Suppliers of the Avenova business will likely have a new business relationship with PRN.

Next Steps

• Stockholders will vote on the asset sale and dissolution at a special meeting on November 22, 2024.
• The company will work to satisfy all closing conditions for the asset sale.
• If approved, the company will proceed with the liquidation and dissolution process.
• The company will distribute remaining assets to stockholders after paying claims and setting aside reserves.

Key Dates

Keywords

asset sale, liquidation, dissolution, eyecare, Avenova, PRN Physician Recommended Nutriceuticals, bridge loan, stockholder distribution, financial challenges, going concern